

STATISTIQUES ET MODÉLISATION POUR LES SCIENCES DE LA SANTÉ

EQUIPE EVALUATION ET MODÉLISATION DES EFFETS THÉRAPEUTIQUES GUEYFFIER François

PROFESSEUR D'UNIVERSITÉ - PRATICIEN HOSPITALIER ÉMÉRITE UCBL

♥ BP8071

69376 LYON cedex 08 (http://maps.google.com/maps?q=BP8071+69376+%20LYON%20cedex%2008) 2 33 04 78 78 57 49 33 04 72 35 72 31

@ <u>Courriel</u>

Professor François GUEYFFIER has more than 30 years of experience in clinical pharmacology and modeling in pharmacology. He coordinated the EU-USA INDANA consortium (http://lbbe-dmz.univ-lyon1.fr/spip_indana/) for performing individual data meta-analyzes (IPDMA) of randomized controlled trials in hypertension (Italy, United Kingdom, Belgium, France, USA, China), leading to more than 20 international publications in this field. This experiment served to illustrate how the IPDMA approach could / should influence the recommendations and design of new randomized controlled trials (doi: 10.1016 / j.jclinepi.2015.05.024). He is the author of 214 publications recorded in Pubmed, 269 according to web of science, H index 36 for WoS.

He coordinated the Clinical Investigation Center (CIC) in Lyon during its first 10 years (2001-2011), as well as the working group on data management in the French CIC network. He helped to establish the requirements for data management centers in the European network ECRIN (http://www.ecrin.org). The data management platform he coordinates in Lyon is ECRIN certified in July 2016 (http://www.ecrin.org/news/two-data-centres-receive-ecrin-certification

). He prepares a recertification for a larger perimeter, including almost all support services for clinical research in Lyon University Hospitals – Hospices Civils de Lyon.

He was PI of the national network for patient recruitment in the IDEAL trial (http://lbbe-dmz.univ-lyon1.fr/spip_ideal/) to identify biomarkers predictive of response to antihypertensive therapy.

He coordinated the BIMBO national consortium (http://lbbe-dmz.univ-lyon1.fr/spip_bimbo/) to help identify markers of antihypertensive drug response by combining the modeling and clinical pharmacology approach.

His team (Dr Patrice NONY and Dr Catherine CORNU) coordinated the European project PriomedChild CRESIM (https://lbbe.univ-lyon1.fr/-CRESIM-.html), to help the choice of the best experimental plan by the simulation of clinical tests.

He teaches clinical pharmacology at the Faculty of Medicine. He is co-head of a master's degree course 2 "pharmacology modeling and clinical trials", local leader of the Inter University Diploma "training clinical trial investigators". He was in charge of organizing experts committees for HCERES, member of selection committees of local and national research projects, member of the Commission de Transparence of Haute Autorité de Santé vice-chief of the Health Data Department of the Hospices Civils de Lyon.